AIDS dorisining hazirqi we kelgusi baziri

Towendiki xewerde eytilishiche AIDS ni dawalashta ishlitidighan
dorilarning sitilish qimmiti 2005-yili 7.1 miliyart (7.1 billion)
dollar bolup, 10 yildin kiyin yeni 2015-yiligha barghanda 10.5
miliyart dollar qimmitige yitidiken.

Hazir AIDS ni dawalashta ishlitidighan dorilarning mutleq kop qismi
nahayti qimmet bolup, adettiki kishilerning istimal sewiyesidin
xilila yuquri. Adettiki Uyghlargha nisbeten hazirche asasen mumkin
diyishke bolidu. Chunki bu dorilarni bir omur uzluksiz toxtatmay
ishlitip turush zorur.


AIDS Drugs Sales to Top $10 Billion by 2015

April 12, 2007

By Ben Hirschler

(Reuters Health) - The launch of new drugs and an increase in the
number of people diagnosed with HIV is set to make AIDS medicine a
$10.6 billion market by 2015, according to a report on Thursday.
Drugmakers may be under pressure to cut prices in the developing
world but selling HIV drugs in the West remains a lucrative and fast-
growing business.

Independent market research firm Datamonitor said the HIV/AIDS market
was set to undergo significant changes over the next 10 years as
drugs that work through novel mechanisms and next-generation versions
of existing drugs are launched.

Sales, as a result, should rise significantly from about $7.1 billion
in 2005, benefiting a clutch of companies with promising new
products, including Merck & Co Inc., Pfizer Inc., Gilead Sciences
Inc. and Johnson & Johnson.

Most cases of HIV/AIDS occur in sub-Saharan Africa, where lack of
funding means treatment is restricted and prices are under pressure,
resulting in little if any profit for multinational drug firms.

Just this week Abbott Laboratories Inc., widely criticised for
aggressive pricing of its AIDS medicines, agreed to slash the price
of its Kaletra AIDS drug by more than half in more than 40 poor
countries.

But at the same time the disease is also increasing in the developed
world, with an estimated 2.1 million people in North America and
Western Europe living with HIV in 2006, up from 1.9 million in 2004.

"Advances in antiretroviral therapy have turned HIV from a
universally feared death sentence into a chronic disease with an
average life expectancy similar to that of Type 2 diabetes,"
Datamonitor analyst Mansi Shah said.

"Because of this, attitudes towards HIV have become relatively blase
amongst some groups."

Notable new types of drugs include Pfizer's maraviroc, a CCR5
inhibitor, and Merck's raltegravir, an integrase inhibitor, which are
expected to be launched in 2007 and 2008 respectively.

They will complement new generation forms of existing drug classes,
such as Johnson & Johnson's recently approved Prezista, a protease
inhibitor.

Such products offer new treatment options for the growing number of
patients whose disease no longer responds to existing drugs.

At the same time, other companies are developing improved fixed-dose
drug combinations, including Atripla from Gilead, which combines the
components of current drug cocktails into a single pill that can be
taken once a day.

Atripla was launched in the United States last year and is expected
to take market share from its two components Truvada and Sustiva, as
well as competitor drugs such as GlaxoSmithKline Plc's Combivir,
Datamonitor said.

The global market for all pharmaceuticals grew 7 percent last year to
$643 billion, according to estimates from another market research
company, IMS Health, released last month.